Immix Biopharma (IMMX) Enterprise Value (2020 - 2026)

Immix Biopharma has disclosed Enterprise Value across 7 years of filings, most recently posting -$90.6 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$90.6 million, down 468.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$90.6 million (down 468.93% YoY), and the FY2025 annual result was -$100.4 million, down 467.97% from the prior year.
• Enterprise Value came in at -$90.6 million for Q1 2026 at Immix Biopharma, up from -$100.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$11.5 million in Q1 2023 to a low of -$100.4 million in Q4 2025.
• The 5-year median for Enterprise Value is -$18.1 million (2022), against an average of -$27.6 million.
• Across the five-year window, Enterprise Value surged 51.62% in 2025 and tumbled 468.93% in 2026, its largest moves.
• Immix Biopharma's Enterprise Value stood at -$16.9 million in 2022, then fell by 4.7% to -$17.7 million in 2023, then advanced by 0.17% to -$17.7 million in 2024, then slumped by 467.97% to -$100.4 million in 2025, then climbed by 9.81% to -$90.6 million in 2026.
• The last three Enterprise Value figures came in at -$90.6 million (Q1 2026), -$100.4 million (Q4 2025), and -$15.9 million (Q3 2025), per Business Quant data.